No matter who writes the story of CRISPR, Emmanuelle Charpentier (founding director, Max Planck Unit for the Science of Pathogens, Berlin) is one of the undisputed heroines of the saga. The French microbiologist played a critical role in launching the field of CRISPR gene editing while moving between labs and countries in her search for a stable and independent research environment. Her contributions leading up to the classic Science paper in 2012, in collaboration with the Jennifer Doudna lab, have been heralded by the community and celebrated with dozens of prestigious scientific awards.

During a flying visit to New York City last autumn, we managed to rendezvous with Charpentier – appropriately in a French bistro – for a candid conversation about her upbringing, motivation, the CRISPR revolution and future plans. (The interview, part of the Guidepost podcast series, is conducted by Kevin Davies, editor-at-large for GEN and executive editor of The CRISPR Journal.)


To listen to additional GuidePost podcasts, click here.


The CRISPR Journal, published by Mary Ann Liebert, Inc., delivers cutting-edge multidisciplinary peer-reviewed research, advances, and commentary on CRISPR, the extraordinary technology that gives scientists the power to cure disease and sculpt evolution.



Previous articleLicensing Deal Moves Merck KGaA, Vertex Further into Gene Editing-Based Drug Development
Next articleShoot the Neurons Off a Fly’s Brain